By Martha Rosenberg, AlterNet. Posted August 28, 2007.Ninety-two percent of FDA advisory meetings in the last decade included a member with financial ties to drug companies. A look at how that affects the drugs that are allowed on the market — even after they’re shown to be deadly. Tools
They’re just dropping like Chinese imports — prescription drugs that turn out to be deadly after FDA approval.
Not just Vioxx — recently found to cause kidney problems on top of the heart attacks for which it was pulled — but its seven deadly sisters named by the FDA’s Dr. David Graham before Congress in 2004: Crestor, Meridia, Serevent, Lotronex, Arava, Accutane and Bextra.
After a post-Vioxx damage control campaign — “FDA has confidence in the safety and efficacy of Crestor” read AstraZeneca ads which the FDA pulled — it wasn’t that confident. The cholesterol drug Crestor was found in the heart journal Circulation to be eight times more likely to cause rhabdomyolysis, kidney failure or spillage of protein in the urine than other cholesterol drugs.